Please login to the form below

Not currently logged in
Email:
Password:

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

AbbVie

AbbVie is to join the crowded field of companies looking to develop the next generation of multiple myeloma treatments, signing a deal with US biotech Teneobio to co-develop and commercialise its B-cell maturation antigen (BCMA) targeting candidate.

TNB-383B is a bispecific antibody which targets the cluster of differentiation 3 (CD3) site as well as BCMA, which the partners hope will give it an edge over more established pipeline molecules.  Coming to the fore in this race are a group of BCMA-targeting CAR-T candidates from Bluebird Bio, Celgene/Juno and Johnson & Johnson/Legend Biotech.

Teneobio’s candidate is similar to Amgen’s AMG420, another bispecific antibody, which recently produced encouraging phase 1 results.  The promise of bispecifics is that if they can match the efficacy of CAR-Ts, they could emerge as the new standard of care, not having the complicated and expensive manufacturing process with the cell therapies, and also potentially producing fewer side-effects.

Teneobio’s drug development platform TeneoSeek helps the company rapidly identify large numbers of unique binding molecules specific for therapeutic targets of interest.

The selected anti-CD3 antibodies from TeneoSeek can be incorporated in bi- or multi-specific antibodies to target and destroy tumour cells.

The company says its platform comes with an added bonus of significantly reducing pro-inflammatory cytokine release, a side-effect frequently seen in CAR-Ts.

Teneobio says its “T-cell engaging cancer therapeutics are of the next wave or promising biologics, rivalling CAR-T cell therapy for efficacy, with the added benefit of off-the shelf dosing and straightforward manufacturability”.

Mohit Trikha, vice president and head, oncology early development, AbbVie said Teneobio's novel approach to T-cell redirection has the potential to be a significant option for patients with myeloma.

AbbVie has paid Teneobio - and its affiliate company TeneoOne - $90m to co-develop and commercialise the candidate, which will continue to be developed by TeneoOne through phase 1.

The agreement also includes an option for AbbVie to buy TeneoOne.

Roland Buelow, CEO of Teneobio and TeneoOne says it alliance with AbbVie will help it progress its lead candidate into trials faster. It expects to begin its phase 1 clinical trial for TNB-383B in the first half of 2019.

12th February 2019

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

Precision paediatrics: Treating patients with CAR-T
Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking...
What does it mean to be an agile organisation
We spoke with Philip Atkinson to learn how healthcare and pharmaceutical companies can rapidly respond to changes in the market....
Battling breast cancer with precision medicine (Part 2)
Dr Mark Moasser treated breast cancer survivor Laura Holmes-Haddad (interviewed in part one) with an innovative precision medicine, which at the time was yet to be approved. Here he gives...

Infographics